Top Biotech Companies (3,701)
Rempex Pharmaceuticals engages in the discovery and development of antibacterial drugs for antibiotic resistance.
Immunetrics takes a Quantitative Systems Pharmacology (QSP) approach to creating mechanistic mathematical models of biological systems, accelerating development of drugs, clinical diagnostics, and medical/commercial devices. We predict FDA-approved endpoints through in silico clinical trial simulations of acute or chronic inflammatory diseases. We deliver proprietary mathematical models encompassing biological pathways and interactions that span levels of detail from intracellular signaling pathways,...
We’re a different kind of biotech company. And we’re here to make a difference. Prometheus Biosciences, Inc. (Nasdaq: RXDX), is a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development and commercialization of novel therapeutic and companion diagnostic products for the treatment of immune-mediated diseases. The Company’s precision medicine platform, Prometheus360™, combines proprietary machine learning-based analytical approaches with...
Catena Biosciences was founded in 2020 based on technology developed in the Francis and Doudna Labs at UC Berkeley. Our platform allows for the rapid coupling of proteins for the creation of novel therapeutics in oncology, autoimmune disorders, and vaccine development. Follow our journey! www.catenabiosciences.com
Preceptis Medical develops surgical tools that allow ear tube procedures to be performed with less pain.
We are an RNA delivery and therapeutics company. Our proprietary Bio-Courier® technology addresses the limitations of other RNA delivery technologies through the hybridization of organic materials with inorganic bioabsorbable silicon. Our Bio-Courier portfolio includes silicon stabilized hybrid lipid nanoparticles (sshLNP) that improve the stability, safety, and transfection efficiency of RNA. We use sshLNP to develop a pipeline of RNA therapeutics...
Dr. Silviu Pharmachem Pvt Ltd (DRSPL), an ISO 9001-2015 certified, is an innovative company that discovers and develops a broad range of chemicals. Pioneer in 'Porphyrin Chemistry' in India and among the largest Porphyrin and Porphyrin Building Blocks manufacturers in the world. We are providing products on milligrams to over several hundred kilograms for research and production purposes.
Entact Bio is a preclinical stage biotechnology company developing a new class of drugs that enhance the function of beneficial proteins. Launched by a founding team deeply rooted in deubiquitinase (DUB) biochemistry, chemical biology, disease biology, and small-molecule drug development, Entact has designed its proprietary Encompass™ platform to create enhancement-targeting chimeric (ENTAC™) medicines. ENTACs harness the ability of DUBs to...
Digital Solid State Propulsion, Inc. is a Nevada based business founded in October 2005.
CardiaLen develops and commercializes pain-free cardioversion therapies for atrial fibrillation.
Gameto is a biotechnology company whose mission is to redefine female reproductive health by developing therapies that improve lives. Women’s health is a vastly underserved therapeutic area. Most conditions have few treatment options, and those available often cause frequent complications and offer limited clinical benefit. We aim to change that. Gameto is committed to using cutting-edge scientific advances to deliver better solutions...
Graphite Bio is a clinical-stage, next-generation gene editing company driven to discover and develop cures for a wide range of serious and life-threatening diseases. The company is pioneering a precision gene editing approach that has the potential to transform human health by achieving one of medicine’s most elusive goals: to precisely “find & replace” any gene in the genome. Graphite...
Almaden Genomics is accelerating genomic discovery with g.nome, a cloud-native platform designed to streamline genomic workflows. Brought to market by a team of bioinformaticians, engineers and industry professionals, Almaden’s g.nome platform allows for a low-code/no-code pipeline build. With a visual drag-and-drop pipeline builder that utilizes toolkits and pre-built workflows from a curated library, g.nome is giving power to researchers —...
IGM Biosciences (Nasdaq: IGMS) is a clinical-stage biotechnology company pioneering the development of engineered IgM antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. IgM antibodies have inherent properties that we believe may enable them to bind more strongly to targets on the surface of cells than comparable IgG antibodies. We believe our proprietary IgM antibody...
Sekisui XenoTech is a pharmaceutical company offering pharmaceutical safety testing and drug metabolism services.
Genesis Therapeutics is unifying AI and biotech to accelerate and optimize drug discovery. We pioneer novel deep learning and molecular simulation techniques to accelerate the development of new medicines. Genesis raised its $52M Series A from top tech + biotech investors, Andreessen Horowitz, Rock Springs, and T. Rowe Price. Story: https://techcrunch.com/2020/12/02/genesis-therapeutics-raises-52m-a-round-for-its-ai-focused-drug-discovery-mission/ We deploy our technology to accelerate a pipeline of several internal drug programs. Furthermore,...
Allinaire Therapeutics aims to develop novel therapeutics for Chronic Obstructive Pulmonary Disease (COPD) and other pulmonary diseases.
Strata Oncology is a precision oncology company dedicated to transforming cancer care.
ENPICOM develops high-performance bioinformatics software and services for biotech and pharmaceutical scientists. Its platform transforms immune-repertoire data into actionable insights for therapeutic and antibody discovery, integrating computational science, immunology, machine learning, and software engineering. The company connects wet-lab and dry-lab workflows, automates analysis, and supports data-driven decisions to accelerate biologics discovery, development, and identification of better drug candidates across modern...
